Publication:
Different Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile

Simple item page
dc.contributor.authorLe Corre, Nicole
dc.contributor.authorAbarca, Katia
dc.contributor.authorAstudillo, Patricio
dc.contributor.authorPotin, Marcela
dc.contributor.authorLópez, Sofía
dc.contributor.authorGoldsack, Macarena
dc.contributor.authorValenzuela, Vania
dc.contributor.authorSchilling Redlich, Andrea
dc.contributor.authorGaete, Victoria
dc.contributor.authorRubio, Lilian
dc.contributor.authorCalvo, Mario
dc.contributor.authorTwele, Loreto
dc.contributor.authorGonzález, Marcela
dc.contributor.authorFuentes, Daniela
dc.contributor.authorGutiérrez, Valentina
dc.contributor.authorReyes, Felipe
dc.contributor.authorTapia, Lorena I.
dc.contributor.authorVillena, Rodolfo
dc.contributor.authorRetamal-Díaz, Angello
dc.contributor.authorCárdenas, Antonio
dc.contributor.authorAlarcón-Bustamante, Eduardo
dc.contributor.authorMeng, Xing
dc.contributor.authorXin, Qianqian
dc.contributor.authorGonzález-Aramundiz, José V.
dc.contributor.authorAlvarez-Figueroa, María Javiera
dc.contributor.authorGonzález, Pablo A.
dc.contributor.authorBueno, Susan M.
dc.contributor.authorSoto, Jorge A.
dc.contributor.authoron behalf of the PedCoronaVac03CL Study Group
dc.contributor.authorPerret, Cecilia
dc.contributor.authorKalergis, Alexis M.
dc.date.accessioned2024-06-05T17:41:31Z
dc.date.available2024-06-05T17:41:31Z
dc.date.issued2023
dc.description.abstractDuring the COVID-19 pandemic, the importance of vaccinating children against SARS-CoV-2 was rapidly established. This study describes the safety of CoronaVac® in children and adolescents between 3- and 17-years-old in a multicenter study in Chile with two vaccine doses in a 4-week interval. For all participants, immediate adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs) were registered throughout the study. In the safety subgroup, AEs were recorded 28 days after each dose. COVID-19 surveillance was performed throughout the study. A total of 1139 individuals received the first and 1102 the second dose of CoronaVac®; 835 were in the safety subgroup. The first dose showed the highest number of AEs: up to 22.2% of participants reported any local and 17.1% systemic AE. AEs were more frequent in adolescents after the first dose, were transient, and mainly mild. Pain at the inoculation site was the most frequent AE for all ages. Fever was the most frequent systemic AE for 3–5 years old and headache in 6–17 years old. No SAEs or AESIs related to vaccination occurred. Most of the COVID-19 cases were mild and managed as outpatients. CoronaVac® was safe and well tolerated in children and adolescents, with different safety patterns according to age.
dc.description.versionVersión publicada
dc.format.extent13 p.
dc.identifier.citationLe Corre N, Abarca K, Astudillo P, Potin M, López S, Goldsack M, Valenzuela V, Schilling A, Gaete V, Rubio L, et al. Different Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile. Vaccines. 2023; 11(10):1526. https://doi.org/10.3390/vaccines11101526
dc.identifier.doihttps://doi.org/10.3390/vaccines11101526
dc.identifier.urihttps://hdl.handle.net/11447/9046
dc.language.isoen
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/cl/
dc.subjectCoronaVac®
dc.subjectSARS-CoV-2
dc.subjectCOVID-19 vaccines
dc.subjectInactivated virus vaccine
dc.subjectSafety pattern
dc.subjectChildren
dc.subjectAdolescents
dc.titleDifferent Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile
dc.typeArticle
dcterms.accessRightsAcceso abierto
dcterms.sourceVaccines
dspace.entity.typePublication
relation.isAuthorOfPublicationc4b84d1b-640f-4b15-94a2-03181f398c50
relation.isAuthorOfPublication.latestForDiscoveryc4b84d1b-640f-4b15-94a2-03181f398c50

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
vaccines-11-01526.pdf
Size:
2.32 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services